Ignite Creation Date:
2024-05-06 @ 10:25 AM
Last Modification Date:
2024-10-26 @ 12:30 PM
Study NCT ID:
NCT03258931
Status:
RECRUITING
Last Update Posted:
2020-05-22
First Post:
2017-08-21
Brief Title:
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Sponsor:
Arog Pharmaceuticals Inc
Organization:
Arog Pharmaceuticals Inc
Organization Data
Organization:
Arog Pharmaceuticals Inc
Class:
INDUSTRY
Study ID:
ARO-021
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Arog Pharmaceuticals Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None